Autologous Bone Marrow Transplant DRG Reimbursement Insights

DRG 017 encompasses autologous bone marrow transplant admissions without Major Complication or Comorbidity and without Complication or Comorbidity; it covers inpatient stays for hematopoietic stem cell infusion and related supportive care. This Diagnosis-Related Group matters for inpatient reimbursement because classification into this group versus groups with higher severity drives Medicare payment weights and overall hospital revenue for transplant episodes.

DRG 017 Overview

DRG 017 covers inpatient hospitalizations for autologous bone marrow transplant procedures without a Major Complication or Comorbidity and without a Complication or Comorbidity. It includes cases where the patient receives autologous hematopoietic stem cell infusion following preparative regimens for hematologic malignancies or other marrow-replacing conditions. This Diagnosis-Related Group matters for Medicare payment because it groups resource use for straightforward transplant admissions, determining bundled payment weights and influencing hospital reimbursement for these specialized services. Accurate coding and documentation of complications or comorbidities affect whether an admission is classified in this Diagnosis-Related Group versus higher-paying groups.

Trials evaluating conditioning regimen optimization prior to autologous bone marrow transplant: These studies compare different myeloablative or reduced-intensity conditioning protocols (dosing schedules, combination chemo regimens, and supportive care adjuncts) in adult patients with hematologic malignancies undergoing autologous transplant. The patient population typically includes those with multiple myeloma, lymphomas, or relapsed leukemias eligible for autologous grafts, and the research question is whether alternative regimens reduce transplant-related toxicity while maintaining disease control. Results are highly relevant to inpatient providers and payers because conditioning choices drive length of stay, complication rates, intensive care utilization, and overall transplant episode costs.
Comparative effectiveness studies of inpatient infection prevention and neutropenia management strategies: These trials test different prophylactic and early-intervention approaches (antimicrobial prophylaxis strategies, central line care bundles, colony-stimulating factor timing, and diagnostic surveillance protocols) in patients during the nadir period after autologous marrow infusion. The target population is hospitalized transplant recipients at high risk for febrile neutropenia and catheter-related infections; the question is which prevention bundles or monitoring strategies reduce bloodstream infections, ICU transfers, and readmissions. Findings inform clinical pathways and reimbursement models because effective prevention reduces costly complications, length of stay, and post-discharge resource use.
Post-discharge outcomes and survivorship trials focusing on recovery, readmission reduction, and cost-effectiveness: These observational and interventional studies evaluate transitional care models, telemonitoring, symptom management programs, and rehabilitation interventions in the weeks to months after inpatient autologous transplant. Participants are survivors discharged after uncomplicated autologous transplants who remain at risk for late infections, cytopenias, or treatment-related morbidity; the objective is to lower 30–90 day readmissions, improve quality of life, and assess total episode-of-care costs. Results guide payers and providers on which post-discharge services or case-management strategies produce better clinical outcomes and are cost-effective within bundled payment or value-based reimbursement frameworks.

Trials evaluating conditioning regimen optimization prior to autologous bone marrow transplant: These studies compare different myeloablative or reduced-intensity conditioning protocols (dosing schedules, combination chemo regimens, and supportive care adjuncts) in adult patients with hematologic malignancies undergoing autologous transplant. The patient population typically includes those with multiple myeloma, lymphomas, or relapsed leukemias eligible for autologous grafts, and the research question is whether alternative regimens reduce transplant-related toxicity while maintaining disease control. Results are highly relevant to inpatient providers and payers because conditioning choices drive length of stay, complication rates, intensive care utilization, and overall transplant episode costs.
Comparative effectiveness studies of inpatient infection prevention and neutropenia management strategies: These trials test different prophylactic and early-intervention approaches (antimicrobial prophylaxis strategies, central line care bundles, colony-stimulating factor timing, and diagnostic surveillance protocols) in patients during the nadir period after autologous marrow infusion. The target population is hospitalized transplant recipients at high risk for febrile neutropenia and catheter-related infections; the question is which prevention bundles or monitoring strategies reduce bloodstream infections, ICU transfers, and readmissions. Findings inform clinical pathways and reimbursement models because effective prevention reduces costly complications, length of stay, and post-discharge resource use.
Post-discharge outcomes and survivorship trials focusing on recovery, readmission reduction, and cost-effectiveness: These observational and interventional studies evaluate transitional care models, telemonitoring, symptom management programs, and rehabilitation interventions in the weeks to months after inpatient autologous transplant. Participants are survivors discharged after uncomplicated autologous transplants who remain at risk for late infections, cytopenias, or treatment-related morbidity; the objective is to lower 30–90 day readmissions, improve quality of life, and assess total episode-of-care costs. Results guide payers and providers on which post-discharge services or case-management strategies produce better clinical outcomes and are cost-effective within bundled payment or value-based reimbursement frameworks.

OpenPayer

Summary & Overview

Autologous Bone Marrow Transplant without CC/MCC: Inpatient Reimbursement Overview

DRG 017 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes